ArticleBritish journal of cancer2006
A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei.
Article in British journal of cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 40 citations in OpenAlex.
- A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei.British journal of cancer · 2008Trial
- Research progress in the diagnosis and treatment of pseudomyxoma peritonei.World journal of surgical oncology · 2026Review
- Review
- A case of Pseudomyxoma Peritonei of an unexpected origin.Diagnostic pathology · 2021Article
- Novel Perspectives in Pseudomyxoma Peritonei Treatment.Cancers · 2021Review
- Role of Epithelial-Mesenchymal Plasticity in Pseudomyxoma Peritonei: Implications for Locoregional Treatments.International journal of molecular sciences · 2020Review
- The biological basis and function of GNAS mutation in pseudomyxoma peritonei: a review.Journal of cancer research and clinical oncology · 2020Review
- [Recurrence of pseudomyxoma peritonei with liver and splenic metastases: about a case and literature review].The Pan African medical journal · 2018Review
- Pathology of Mucinous Appendiceal Tumors and Pseudomyxoma Peritonei.Indian journal of surgical oncology · 2016Review
- Patient-derived xenograft mouse models of pseudomyxoma peritonei recapitulate the human inflammatory tumor microenvironment.Cancer medicine · 2016Article
- Pathophysiology and classification of pseudomyxoma peritonei.Pleura and peritoneum · 2016Review
- Global gene expression in pseudomyxoma peritonei, with parallel development of two immortalized cell lines.Oncotarget · 2015Article
- Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects.Orphanet journal of rare diseases · 2014Review
- Pulmonary metastasis from pseudomyxoma peritonei.Gastroenterology research and practice · 2012Article
- Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies.PloS one · 2010Article
- Reciprocal relationship between expression of hypoxia inducible factor 1alpha (HIF-1alpha) and the pro-apoptotic protein bid in ex vivo colorectal cancer.British journal of cancer · 2008Article
- Pseudomyxoma peritonei--two novel orthotopic mouse models portray the PMCA-I histopathologic subtype.BMC cancer · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudomyxoma peritonei (PMP) is a rare neoplasm of mainly appendiceal origin, characterised by excess intra-abdominal mucin production leading to high morbidity and mortality. While histological features are frequently indolent, this tumour disseminates aggressively throughout the abdominal cavity, yet seldom metastasises. This study determined the expression of several markers of colorectal differentiation (carcinoembryonic antigen (CEA), cytokeratins (CK20 and CK7), epithelial membrane antigen), mucin production (MUC-2, interleukin-9 (IL-9), IL-9 receptor (IL-9Ralpha)), and cell adhesion (N- and E-cadherin, vimentin) in PMP tissue (n=26) compared with expressions in normal colonic mucosa (n=19) and colorectal adenocarcinoma (n=26). Expressions of CEA and cytokeratins were similar for PMP as those in colorectal adenocarcinomas with the exception that the CK20-/CK7- pattern was rare in PMP (Fisher's exact test: P=0.001). Similarly, expressions of mucin-related proteins were comparable for adenocarcinoma and PMP, with the exception that IL-9 expression was uncommon in adenocarcinoma (P=0.009). Pseudomyxoma peritonei demonstrated a specific pattern of adhesion-related protein expressions of increased N-cadherin, reduced E-cadherin, and increased vimentin (P=0.004), a phenotype suggesting a possible epithelial-mesenchymal transition state. Primary PMP cell cultures were successfully maintained and demonstrated marker expressions similar to those seen in in vivo tissues. These early characterisation studies demonstrate similarities between PMP and colorectal adenocarcinoma, but also reveal a specific cadherin phenotype that may characterise the distinct non-metastasising behaviour of PMP, and form the basis for future mechanistic and therapy-targeting research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.